Physician profile
John C Strunk
NPI 1811983596
$25,732.30
in general payments reported to CMS, 2019-2025
36 companies · $4,123 in 2025
The $4,123 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $1,542 · 2021: $2,344 · 2022: $2,991 · 2023: $9,134 · 2024: $3,997 · 2025: $4,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,625 · Travel and Lodging: $743 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,655.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,625.00 |
| Travel and Lodging | $743.05 |
| Education | $230.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $5,700.04 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $2,765.78 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,642.67 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,478.18 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Neurocrine Biosciences, INC. | $1,399.25 | 2019-2025 | Ingrezza |
| Tris Pharma INC | $1,306.43 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Alkermes, INC. | $1,291.99 | 2019-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $1,267.46 | 2019-2024 | Jornay Pm |
| Corium, LLC | $1,242.73 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $1,168.10 | 2024-2025 | Fanapt |
| Harmony Biosciences LLC | $726.23 | 2020-2025 | Wakix |
| Avanir Pharmaceuticals, INC. | $688.90 | 2019-2022 | |
| Axsome Therapeutics, INC. | $605.59 | 2023-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $523.87 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $493.83 | 2022-2024 | Quviviq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $471.14 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $456.38 | 2021-2025 | Caplyta |
| Allergan, INC. | $383.28 | 2019-2020 | |
| Lundbeck LLC | $351.09 | 2019-2025 | Rexulti |
| Neos Therapeutics, LP | $347.45 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Merck Sharp & Dohme LLC | $321.65 | 2020-2023 | Belsomra |
| Eisai INC. | $234.83 | 2020-2022 | |
| Lilly USA, LLC | $131.95 | 2020-2024 | Amyvid |
| Pfizer INC. | $126.11 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $109.46 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $103.44 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $76.67 | 2019-2024 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $75.71 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $32.19 | 2021 | |
| Neuronetics, INC. | $29.80 | 2019-2021 | |
| Adlon Therapeutics L.P. | $27.28 | 2020-2021 | |
| Indivior INC. | $27.10 | 2019 | |
| Collegium Pharmaceutical, INC. | $18.49 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $17.82 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Strunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.